3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Filgrastim
10
Ifosfamide
6
Carboplatin
5
Radiotherapy
4
Peripheral Blood Stem Cell Transplantation
4
Doxorubicin
4
Cyclophosphamide
4
pembrolizumab
3
Thiotepa
3
Temozolomide
3
Etoposide
3
Busulfan
3
sargramostim
2
ixabepilone
2
fludarabine phosphate
2
etoposide phosphate
2
belinostat
2
Radiotherapy, Intensity-Modulated
2
Radiosurgery
2
Paclitaxel
2
Mycophenolic Acid
2
Melphalan
2
Granulocyte Colony-Stimulating Factor
2
Gemcitabine
2
Bortezomib
2
Antilymphocyte Serum
2
Amifostine
2
tremelimumab
1
seribantumab
1
poly ICLC
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
Genetic Counseling
×
Sarcoma
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled